Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Forecast & Price Target
Aardvark Therapeutics, Inc. Common Stock · NASDAQ
$5.30-0.08 (-1.49%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Aardvark Therapeutics, Inc. Common Stock, 4 rate it Buy or better, 4 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $33.00 (about 11.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $11.38 sits 115% above the current $5.30. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.74 next quarter toward $-2.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy444%
Hold444%
Sell111%
Strong Sell00%
Based on 9 analysts giving stock ratings to Aardvark Therapeutics, Inc. Common Stock.
As of Sep, 4 of 9 firms rate AARD a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
AARD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.74
Range $-1.10 – $-0.42 · 9 analysts · -9% YoY
Next period, 9 analysts expect Aardvark Therapeutics, Inc. Common Stock to earn $-0.74 a share (range $-1.10 – $-0.42), versus $-0.81 a year earlier. Full-year consensus is $-3.17, growing to $-2.78 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Aardvark Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AARD.
#1
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$50.00+843.4% to target
Overall win rate
38%
+ Follow
#2
Leland Gershell
Oppenheimer · Rank #307
Buy
$21.00+296.2% to target
Overall win rate
37%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Hold
$6.00+13.2% to target
Overall win rate
36%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #317
Sell
$4.00-24.5% to target
Overall win rate
47%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #371
Hold
$6.00+13.2% to target
Overall win rate
28%
+ Follow
AARD stock forecast FAQ
What is AARD's average 12-month price target?+
The 7 analysts with a live target average $11.38 for Aardvark Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $33.00 high to a $3.00 low.
Is AARD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 4 are Buy or Strong Buy, 4 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for AARD?+
The Street-high target is $33.00 (Jones Trading), and the Street-low is $3.00 (Morgan Stanley). The average of all 7 active targets is $11.38.
How many Wall Street analysts cover AARD?+
9 analysts have an active rating on Aardvark Therapeutics, Inc. Common Stock, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering AARD?+
Among analysts who currently cover AARD, Josh Schimmer of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $50.00 target.
What is Aardvark Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.74 per share (range $-1.10 – $-0.42) across 9 analysts. Full-year EPS is projected at $-3.17, rising to $-2.78 the following year.
How much revenue is Aardvark Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AARD lately?+
As of Sep, 4 of 9 firms rate AARD a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AARD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
